Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

CD4 T cell-restricted IL-2 signaling defect in a patient with a novel IFNGR1 deficiency.

Khanolkar A, Kirschmann DA, Caparelli EA, Wilks JD, Cerullo JM, Bergerson JRE, Jennings LJ, Fuleihan RL.

J Allergy Clin Immunol. 2018 Jan;141(1):435-439.e7. doi: 10.1016/j.jaci.2017.08.018. Epub 2017 Sep 18. No abstract available.

PMID:
28927822
2.

Divergence(s) in nodal signaling between aggressive melanoma and embryonic stem cells.

Khalkhali-Ellis Z, Kirschmann DA, Seftor EA, Gilgur A, Bodenstine TM, Hinck AP, Hendrix MJ.

Int J Cancer. 2015 Mar 1;136(5):E242-51. doi: 10.1002/ijc.29198. Epub 2014 Sep 29.

3.

Nodal signaling promotes a tumorigenic phenotype in human breast cancer.

Kirsammer G, Strizzi L, Margaryan NV, Gilgur A, Hyser M, Atkinson J, Kirschmann DA, Seftor EA, Hendrix MJ.

Semin Cancer Biol. 2014 Dec;29:40-50. doi: 10.1016/j.semcancer.2014.07.007. Epub 2014 Jul 26. Review.

4.

Tumor cell vasculogenic mimicry: from controversy to therapeutic promise.

Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, Hendrix MJ.

Am J Pathol. 2012 Oct;181(4):1115-25. doi: 10.1016/j.ajpath.2012.07.013. Epub 2012 Aug 31. Review.

5.

Nodal expression and detection in cancer: experience and challenges.

Strizzi L, Hardy KM, Kirschmann DA, Ahrlund-Richter L, Hendrix MJ.

Cancer Res. 2012 Apr 15;72(8):1915-20. doi: 10.1158/0008-5472.CAN-11-3419. Review.

6.

Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications.

Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ.

Clin Cancer Res. 2012 May 15;18(10):2726-32. doi: 10.1158/1078-0432.CCR-11-3237. Epub 2012 Apr 2.

7.
8.

Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype.

Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, Strizzi L, Hendrix MJ.

Cancer Res. 2010 Dec 15;70(24):10340-50. doi: 10.1158/0008-5472.CAN-10-0705.

9.

New insights into cathepsin D in mammary tissue development and remodeling.

Margaryan NV, Kirschmann DA, Lipavsky A, Bailey CM, Hendrix MJ, Khalkhali-Ellis Z.

Cancer Biol Ther. 2010 Sep 1;10(5):457-66. Epub 2010 Oct 1.

10.

Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion.

Santhanam AN, Baker AR, Hegamyer G, Kirschmann DA, Colburn NH.

Oncogene. 2010 Jul 8;29(27):3921-32. doi: 10.1038/onc.2010.158. Epub 2010 May 24.

11.

Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment.

Costa FF, Seftor EA, Bischof JM, Kirschmann DA, Strizzi L, Arndt K, Bonaldo Mde F, Soares MB, Hendrix MJ.

Epigenomics. 2009 Dec;1(2):387-98. doi: 10.2217/epi.09.25.

12.

Development and cancer: at the crossroads of Nodal and Notch signaling.

Strizzi L, Hardy KM, Seftor EA, Costa FF, Kirschmann DA, Seftor RE, Postovit LM, Hendrix MJ.

Cancer Res. 2009 Sep 15;69(18):7131-4. doi: 10.1158/0008-5472.CAN-09-1199. Epub 2009 Sep 8. Review.

13.

Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells.

Postovit LM, Margaryan NV, Seftor EA, Kirschmann DA, Lipavsky A, Wheaton WW, Abbott DE, Seftor RE, Hendrix MJ.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4329-34. doi: 10.1073/pnas.0800467105. Epub 2008 Mar 11.

14.

Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration.

Postovit LM, Abbott DE, Payne SL, Wheaton WW, Margaryan NV, Sullivan R, Jansen MK, Csiszar K, Hendrix MJ, Kirschmann DA.

J Cell Biochem. 2008 Apr 1;103(5):1369-78.

PMID:
17685448
15.

Paradoxical roles for lysyl oxidases in cancer--a prospect.

Payne SL, Hendrix MJ, Kirschmann DA.

J Cell Biochem. 2007 Aug 15;101(6):1338-54. Review.

PMID:
17471532
16.

A requirement for dimerization of HP1Hsalpha in suppression of breast cancer invasion.

Norwood LE, Moss TJ, Margaryan NV, Cook SL, Wright L, Seftor EA, Hendrix MJ, Kirschmann DA, Wallrath LL.

J Biol Chem. 2006 Jul 7;281(27):18668-76. Epub 2006 Apr 28.

17.

The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment.

Seftor EA, Meltzer PS, Kirschmann DA, Margaryan NV, Seftor RE, Hendrix MJ.

J Cell Mol Med. 2006 Jan-Mar;10(1):174-96.

18.

Lysyl oxidase regulates actin filament formation through the p130(Cas)/Crk/DOCK180 signaling complex.

Payne SL, Hendrix MJ, Kirschmann DA.

J Cell Biochem. 2006 Jul 1;98(4):827-37.

PMID:
16440329
19.

Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia.

van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, Tran MG, Sciot R, Hauben E, Hogendoorn PC, Delattre O, Maxwell PH, Hendrix MJ, Griffioen AW.

Cancer Res. 2005 Dec 15;65(24):11520-8.

20.

Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism.

Payne SL, Fogelgren B, Hess AR, Seftor EA, Wiley EL, Fong SF, Csiszar K, Hendrix MJ, Kirschmann DA.

Cancer Res. 2005 Dec 15;65(24):11429-36.

21.

Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment.

Seftor EA, Brown KM, Chin L, Kirschmann DA, Wheaton WW, Protopopov A, Feng B, Balagurunathan Y, Trent JM, Nickoloff BJ, Seftor RE, Hendrix MJ.

Cancer Res. 2005 Nov 15;65(22):10164-9.

22.

Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells.

van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW, Hendrix MJ.

J Natl Cancer Inst. 2004 Oct 6;96(19):1473-7.

PMID:
15467037
23.

Conserved properties of HP1(Hsalpha).

Norwood LE, Grade SK, Cryderman DE, Hines KA, Furiasse N, Toro R, Li Y, Dhasarathy A, Kladde MP, Hendrix MJ, Kirschmann DA, Wallrath LL.

Gene. 2004 Jul 7;336(1):37-46.

PMID:
15225874
24.

Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen.

Khalkhali-Ellis Z, Christian AL, Kirschmann DA, Edwards EM, Rezaie-Thompson M, Vasef MA, Gruman LM, Seftor RE, Norwood LE, Hendrix MJ.

Clin Cancer Res. 2004 Jan 15;10(2):449-54.

25.

Remodeling of the microenvironment by aggressive melanoma tumor cells.

Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE.

Ann N Y Acad Sci. 2003 May;995:151-61. Review.

PMID:
12814947
27.

Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry.

Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, Kirschmann DA, Seftor RE, Hendrix MJ.

Crit Rev Oncol Hematol. 2002 Oct;44(1):17-27. Review.

PMID:
12398997
28.

A molecular role for lysyl oxidase in breast cancer invasion.

Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K, Hendrix MJ.

Cancer Res. 2002 Aug 1;62(15):4478-83.

29.

Does heterochromatin protein 1 always follow code?

Li Y, Kirschmann DA, Wallrath LL.

Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16462-9. Epub 2002 Jul 31. Review.

30.

Molecular determinants of human uveal melanoma invasion and metastasis.

Seftor EA, Meltzer PS, Kirschmann DA, Pe'er J, Maniotis AJ, Trent JM, Folberg R, Hendrix MJ.

Clin Exp Metastasis. 2002;19(3):233-46.

PMID:
12067204
31.

The tumour suppressor gene maspin is differentially regulated in cytotrophoblasts during human placental development.

Dokras A, Gardner LM, Kirschmann DA, Seftor EA, Hendrix MJ.

Placenta. 2002 Apr;23(4):274-80.

PMID:
11969337
32.

Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry.

Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE.

Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8018-23. Epub 2001 Jun 19.

33.

Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells.

Hendrix MJ, Seftor EA, Kirschmann DA, Seftor RE.

Breast Cancer Res. 2000;2(6):417-22. Epub 2000 Aug 11. Review.

34.

Estrogen and progesterone regulation of human fibroblast-like synoviocyte function in vitro: implications in rheumatoid arthritis.

Khalkhali-Ellis Z, Seftor EA, Nieva DR, Handa RJ, Price RH Jr, Kirschmann DA, Baragi VM, Sharma RV, Bhalla RC, Moore TL, Hendrix MJ.

J Rheumatol. 2000 Jul;27(7):1622-31.

PMID:
10914842
35.

Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer.

Kirschmann DA, Lininger RA, Gardner LM, Seftor EA, Odero VA, Ainsztein AM, Earnshaw WC, Wallrath LL, Hendrix MJ.

Cancer Res. 2000 Jul 1;60(13):3359-63.

36.

Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients.

Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellers TA, Hendrix MJ.

Clin Cancer Res. 1999 Oct;5(10):2698-703.

37.

C1q-containing immune complexes purified from sera of juvenile rheumatoid arthritis patients mediate IL-8 production by human synoviocytes: role of C1q receptors.

Khalkhali-Ellis Z, Bulla GA, Schlesinger LS, Kirschmann DA, Moore TL, Hendrix MJ.

J Immunol. 1999 Oct 15;163(8):4612-20.

38.

Differentially expressed genes associated with the metastatic phenotype in breast cancer.

Kirschmann DA, Seftor EA, Nieva DR, Mariano EA, Hendrix MJ.

Breast Cancer Res Treat. 1999 May;55(2):127-36.

PMID:
10481940
39.

A novel immunological model for the study of prostate cancer.

Sharma N, Luo J, Kirschmann DA, O'Malley Y, Robbins ME, Akporiaye ET, Lubaroff DM, Heidger PM, Hendrix MJ.

Cancer Res. 1999 May 15;59(10):2271-6.

40.

Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF).

Hendrix MJ, Seftor EA, Seftor RE, Kirschmann DA, Gardner LM, Boldt HC, Meyer M, Pe'er J, Folberg R.

Am J Pathol. 1998 Apr;152(4):855-63.

41.

The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis.

Chauhan B, Santiago L, Kirschmann DA, Hauptfeld V, Knutsen AP, Hutcheson PS, Woulfe SL, Slavin RG, Schwartz HJ, Bellone CJ.

J Immunol. 1997 Oct 15;159(8):4072-6.

PMID:
9378997
42.

A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferation.

Woulfe SL, Bono CP, Zacheis ML, Welply JK, Kirschmann DA, Baudino TA, Wang Y, Stone DA, Hanson GJ, Vuletich JL, Bedell LJ, Schwartz BD, Howard SC.

J Pharmacol Exp Ther. 1997 May;281(2):663-9.

PMID:
9152371
43.

Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles.

Kirschmann DA, Duffin KL, Smith CE, Welply JK, Howard SC, Schwartz BD, Woulfe SL.

J Immunol. 1995 Dec 15;155(12):5655-62.

PMID:
7499850
44.

Negatively charged residues interacting with the p4 pocket confer binding specificity to DRB1*0401.

Woulfe SL, Bono CP, Zacheis ML, Kirschmann DA, Baudino TA, Swearingen C, Karr RW, Schwartz BD.

Arthritis Rheum. 1995 Dec;38(12):1744-53.

PMID:
8849346
45.

Utilization of soluble fusion proteins for induction of T cell proliferation.

Kirschmann DA, De Ciechi PA, Bono CP, Zacheis ML, Schwartz BD, Woulfe SL.

Cell Immunol. 1995 Feb;160(2):193-8.

PMID:
7720079
46.
47.

Differences between young and aged mice in susceptibility to Friend virus.

Stewart DR, Kirschmann DA, Blank KJ, Murasko DM.

Mech Ageing Dev. 1994 Feb;73(2):145-55.

PMID:
7519701
48.
49.
50.

Supplemental Content

Loading ...
Support Center